Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections

Publisher： John Wiley & Sons Inc

E-ISSN： 1439-0507|58|6|362-367

ISSN： 0933-7407

Source： MYCOSES (ELECTRONIC), Vol.58, Iss.6, 2015-06, pp. : 362-367

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high‐risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real‐world comparison

By  

MYCOSES (ELECTRONIC), Vol. 61, Iss. 3, 2018-03 ,pp. : 206-212

John Wiley & Sons Inc

Access to resources Recommend Favorite

Approaches to Induction Therapy with Adult Acute Myeloid Leukaemia

By  

Acta Haematologica, Vol. 99, Iss. 3, 1998-04 ,pp. : 133-137

Karger

Access to resources Recommend Favorite

Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single‐centre retrospective study in Korea and clinical considerations

By  

MYCOSES (ELECTRONIC), Vol. 58, Iss. 9, 2015-09 ,pp. : 565-571

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combined medico‐surgical strategy for invasive sino‐orbito‐cerebral breakthrough fungal infection with Hormographiella aspergillata in an acute leukaemia patient

By  

MYCOSES (ELECTRONIC), Vol. 58, Iss. 5, 2015-05 ,pp. : 308-312

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-Effectiveness of Posaconazole Compared with Standard Azole Therapy for Prevention of Invasive Fungal Infections in Patients at High Risk in Switzerland

By  

Oncology, Vol. 78, Iss. 3-4, 2010-04 ,pp. : 172-180

Karger

Access to resources Recommend Favorite